1. Roberts L.C., Morrow J.D. (2001). Analgesic-Antipiretic and Antiinflammatory Agents and Drugs employed in the treatment of Gout. In: (Hardman JG, Limbird LE., eds) Goodman&Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. McGraw Hill, mt. Ed., pp.687–731.
2. Benvenuti C., Gambaro V., Lodi F., Scaroni C., Bandi G., Valenti M. (1989). Single-dose pharmacokinetics of flurbiprofen granules and tablets in healthy volunteers. mt. J. Clin. Pharnacol. Ther. Toxicol., 27, 334–337.
3. Jamali F., Collins D.S., Berry B.W., Molder S., Cheung R., McColl K., Cheung H. (1991). Comparative bioavailability of two flurbiprofen products: stereospesific versus conventional approach. Biophanm Drug Dispos., 13, 383–387.
4. Townsend K.P., Praticô D. (2005). Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal antiinflammatory drugs. Faseb. J., 19, 192–601.
5. Hassan Y., Alfadly SO., Azmin M.N., Peh K.K., Tan TF.Y., Noorizan A.A., Ismail 0. (2007). Bioequivalence evaluation of two different formulations of ciprofloxacin tablets in healthy volunteers. Singapore Med. J., 48, 819–823.